29.08.2017 Views

Global Vaccines Market Share and Forecast

For more Information: http://www.renub.com/global-vaccine-market-to-reach-usd-60-billion-by-the-end-of-year-2022-49-nd.php Global vaccine market is probable to reach US$ 60 Billion by the end of year 2022 says the recent report published by Renub Research entitled “Global Vaccines Market & Forecast” by 14 vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, Dtap, Travel and Miscellaneous, Haemophilus Influenzae Type b (Hib), Combos, Polio, Rotavirus, Varicella), number of immunized person, number of vaccines doses administered and company sales – forecast to 2022. Vaccines Prevent Diseases With so many diseases in the world, there needs to be something to protect people from getting sick and even dying. So, we have vaccines to protect ourselves from getting sick. In simple words, Vaccines immunize and protect people from several serious diseases such as measles, meningitis, pneumonia, Influenza, rubella and polio. Era of Vaccines A number of vaccines have been developed (e.g. cervical cancer and dengue vaccine) and several others are already on its way to hit the market at earliest (e.g. malaria and zika vaccines), making last 15 years the most productive in the history of vaccines development.

For more Information: http://www.renub.com/global-vaccine-market-to-reach-usd-60-billion-by-the-end-of-year-2022-49-nd.php
Global vaccine market is probable to reach US$ 60 Billion by the end of year 2022 says the recent report published by Renub Research entitled “Global Vaccines Market & Forecast” by 14 vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, Dtap, Travel and Miscellaneous, Haemophilus Influenzae Type b (Hib), Combos, Polio, Rotavirus, Varicella), number of immunized person, number of vaccines doses administered and company sales – forecast to 2022.

Vaccines Prevent Diseases
With so many diseases in the world, there needs to be something to protect people from getting sick and even dying. So, we have vaccines to protect ourselves from getting sick. In simple words, Vaccines immunize and protect people from several serious diseases such as measles, meningitis, pneumonia, Influenza, rubella and polio.

Era of Vaccines
A number of vaccines have been developed (e.g. cervical cancer and dengue vaccine) and several others are already on its way to hit the market at earliest (e.g. malaria and zika vaccines), making last 15 years the most productive in the history of vaccines development.

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Global</strong> Vaccine <strong>Market</strong> to reach USD 60 Billion, by the end of year 2022<br />

<strong>Global</strong> Vaccine <strong>Market</strong> to reach USD 60 Billion, by the end<br />

of year 2022<br />

Analyst View:<br />

<strong>Global</strong> <strong>Vaccines</strong> <strong>Market</strong> to reach US$ 60 Billion by the year 2022. Pediatric vaccines market is<br />

having a dominant market share compared to Adult vaccines market. By 2022 Pediatric<br />

vaccines market share will be double the size of adult vaccines market share.<br />

For More Information:<br />

http://www.renub.com/global-vaccine-market-to-reach-usd-60-billion-by-the-end-of-year-<br />

2022-49-nd.php<br />

Access Full Research: http://www.renub.com/global-vaccines-market-<strong>and</strong>-forecast-<br />

14-vaccines-market-number-of-people-immunized-doses-of-vaccines-administered-<br />

1200-p.php<br />

Get 10% Free Customization in this Report<br />

<strong>Global</strong> vaccine market is probable to reach US$ 60 Billion by the end of year 2022 says the<br />

recent report published by Renub Research entitled “<strong>Global</strong> <strong>Vaccines</strong> <strong>Market</strong> & <strong>Forecast</strong>” by 14<br />

vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis,<br />

Dtap, Travel <strong>and</strong> Miscellaneous, Haemophilus Influenzae Type b (Hib), Combos, Polio,<br />

Rotavirus, Varicella), number of immunized person, number of vaccines doses administered <strong>and</strong><br />

company sales – forecast to 2022.<br />

<strong>Vaccines</strong> Prevent Diseases<br />

With so many diseases in the world, there needs to be something to protect people from getting<br />

sick <strong>and</strong> even dying. So, we have vaccines to protect ourselves from getting sick. In simple<br />

words, <strong>Vaccines</strong> immunize <strong>and</strong> protect people from several serious diseases such as measles,<br />

meningitis, pneumonia, Influenza, rubella <strong>and</strong> polio.<br />

© Renub Research LLP Page 1 of 4


<strong>Global</strong> Vaccine <strong>Market</strong> to reach USD 60 Billion, by the end of year 2022<br />

Era of <strong>Vaccines</strong><br />

A number of vaccines have been developed (e.g. cervical cancer <strong>and</strong> dengue vaccine) <strong>and</strong><br />

several others are already on its way to hit the market at earliest (e.g. malaria <strong>and</strong> zika<br />

vaccines), making last 15 years the most productive in the history of vaccines development.<br />

Industrialized countries already have a robust system of immunization programmes while<br />

developing countries are trying their best to implement such programmes to save a million<br />

lives.<br />

Request a free sample copy of the report: http://www.renub.com/contactus.php<br />

Vaccine <strong>Market</strong> Briefing<br />

Pneumococcal vaccine is the largest segment for vaccine <strong>and</strong> it terms of value it accounts more<br />

than US$ 7 Billion in 2016. The Pneumococcal vaccine sale is primarily driven by increasing<br />

utilization of Pneumococcal vaccines products worldwide, <strong>and</strong> especially in the US, where the<br />

Advisory Committee on Immunization Practices (ACIP) strictly recommends its inoculation.<br />

While there is also a considerable boost in the market size of Cervical Cancer Vaccine as many<br />

countries around the world efficiently focused on the causalities caused by this disease, thus<br />

recommend all women must get Cervical Cancer Vaccine to prevent cervical cancer.<br />

Table of Contents<br />

1. Research Findings<br />

2. <strong>Global</strong> – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

3. <strong>Global</strong> – Adult Vaccine vs. Pediatric Vaccine <strong>Market</strong> <strong>Share</strong><br />

4. <strong>Global</strong> – <strong>Vaccines</strong> <strong>Market</strong> <strong>Share</strong> <strong>and</strong> <strong>Forecast</strong><br />

5. <strong>Global</strong> – People Immunized <strong>and</strong> <strong>Forecast</strong><br />

6. <strong>Global</strong> – People Immunized <strong>Share</strong> <strong>and</strong> <strong>Forecast</strong><br />

7. <strong>Global</strong> – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

8. <strong>Global</strong> – Doses of <strong>Vaccines</strong> Administered <strong>Share</strong> <strong>and</strong> <strong>Forecast</strong><br />

9. <strong>Global</strong> – Vaccine Companies <strong>Market</strong> <strong>Share</strong> <strong>and</strong> <strong>Forecast</strong><br />

10. Disease wise – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.1 Influenza – Total <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.2 Cervical Cancer (HPV) – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.3 Zoster (Shingles) – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

© Renub Research LLP Page 2 of 4


<strong>Global</strong> Vaccine <strong>Market</strong> to reach USD 60 Billion, by the end of year 2022<br />

10.4 MMRV <strong>and</strong> MMR (Measles, Mumps, Rubella, <strong>and</strong> Varicella Vaccine) – Total <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong><br />

<strong>Forecast</strong><br />

10.5 Pneumococcal – Total <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.6 Meningococcal – Total <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.7 Hepatitis – Total <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.8 TdaP <strong>and</strong> DTaP – Total <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.9 Travel <strong>and</strong> Miscellaneous – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.10 Haemophilus Influenzae Type B (HIB) – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.11 Combos (Combination) – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.12 Polio – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.13 Rotavirus – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

10.14 Varicella – <strong>Vaccines</strong> <strong>Market</strong> <strong>and</strong> <strong>Forecast</strong><br />

11. Disease wise – People Immunized Numbers <strong>and</strong> <strong>Forecast</strong><br />

11.1 Influenza – Total Number of People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.2 Cervical Cancer (HPV) – People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.3 Zoster (Shingles) – Number of People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.4 MMRV <strong>and</strong> MMR – Total Number of People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.5 Pneumococcal – Total Number of People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.6 Meningococcal – Total Number of People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.7 Hepatitis – Total Number of People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.8 TdaP <strong>and</strong> DTaP – Total Number of People Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.9 Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.10 Combos (Combination <strong>Vaccines</strong>) – Number of Infants Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.11 Polio – Number of Infants Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.12 Rotavirus – Number of Infants Immunized <strong>and</strong> <strong>Forecast</strong><br />

11.13 Varicella – Number of Infants Immunized <strong>and</strong> <strong>Forecast</strong><br />

12. Disease wise – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.1 Influenza – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.2 Cervical Cancer (HPV) – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.3 Zoster (Shingles) – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.4 MMRV <strong>and</strong> MMR – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.5 Pneumococcal – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.6 Meningococcal – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.7 Hepatitis – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.8 TdaP <strong>and</strong> DTaP – Doses of <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.9 Hib (Haemophilus Influenzae Type B) – Doses of Infant <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.10 Polio – Doses of Infant <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.11 Rotavirus – Doses of Infant <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

12.12 Varicella – Doses of Infant <strong>Vaccines</strong> Administered <strong>and</strong> <strong>Forecast</strong><br />

13. Disease wise - Immunization Profile<br />

13.1 Immunization Coverage (%) in Infants (2005 – 2015)<br />

13.2 <strong>Global</strong> Immunization Profile (2011 – 2015)<br />

13.3 Regional Immunization Profile (2001 – 2015)<br />

14. <strong>Vaccines</strong> Key Players Sales <strong>and</strong> <strong>Forecast</strong><br />

14.1 GlaxoSmithKline, plc.’s <strong>Vaccines</strong> Sales <strong>and</strong> <strong>Forecast</strong><br />

14.2 Merck & Co. <strong>Vaccines</strong> Sales <strong>and</strong> <strong>Forecast</strong><br />

14.3 Sanofi Pasteur’s <strong>Vaccines</strong> Sales <strong>and</strong> <strong>Forecast</strong><br />

14.4 Worldwide - Pfizer, Inc.’s <strong>Vaccines</strong> Sales <strong>and</strong> <strong>Forecast</strong><br />

14.5 Worldwide - Others <strong>Vaccines</strong> Sales <strong>and</strong> <strong>Forecast</strong><br />

15. <strong>Vaccines</strong> – Products <strong>and</strong> Pipeline<br />

15.1 GSK Vaccine Product Pipeline<br />

© Renub Research LLP Page 3 of 4


<strong>Global</strong> Vaccine <strong>Market</strong> to reach USD 60 Billion, by the end of year 2022<br />

15.2 Merck Vaccine Product Pipeline<br />

15.3 Sanofi Vaccine Product Pipeline<br />

15.4 Pfizer Vaccine Product Pipeline<br />

16. Top Mergers <strong>and</strong> Acquisitions in the Vaccine Industry<br />

17. <strong>Vaccines</strong> <strong>and</strong> Regulator’s Interventions<br />

18. Vaccine <strong>Market</strong> Drivers<br />

18.1 Inclusion in National Immunization Schedule<br />

18.2 Growing Immunization Coverage for HPV <strong>Vaccines</strong><br />

18.3 Increase in Prevalence of Infectious Diseases<br />

18.4 <strong>Global</strong> Immunization Vision <strong>and</strong> Strategy (GIVS)<br />

18.5 GAVI Model Fuelling Vaccine Manufacturers<br />

18.6 Increasing Vaccine Availability in United States<br />

18.7 The Vaccine Safety Data link Project<br />

18.8 The Vaccine Injury Compensation Program<br />

18.9 Transforming of Vaccine Technologies<br />

18.10 <strong>Global</strong> Vaccine Action Plan by WHO (2011 - 2020)<br />

18.11 Continuous Focus on Effective Communication Strategies<br />

19. <strong>Vaccines</strong> <strong>Market</strong> Challenges<br />

19.1 Hurdles to Optimal use of Licensed <strong>Vaccines</strong><br />

19.2 Complexity of Vaccine Development & Approval System Thwarts Product Development<br />

19.3 Shortening the Timeline for Vaccine Development<br />

19.4 Refusal/Resistance to Vaccination<br />

19.5 Vaccine Shortages <strong>and</strong> Delays<br />

19.6 Obstacles in Vaccine Research & Development<br />

19.7 Barriers to New Entrants in the <strong>Vaccines</strong> <strong>Market</strong><br />

<strong>Vaccines</strong> <strong>Market</strong> Report:<br />

http://www.renub.com/vaccines-12-c.php<br />

Renub Research - North America<br />

Rajat Gupta<br />

225 Kristie Ln, Roswell<br />

Georgia 30076, United States<br />

Renub Research - Asia<br />

Ankit Mishra<br />

C – 86, Sector – 10<br />

Noida 201301, India<br />

Tel: +1-678-302-0700<br />

Email: info@renub.com<br />

www.renub.com<br />

Tel: +91-120-421-9822<br />

Email: info@renub.com<br />

www.renub.com<br />

© Renub Research LLP Page 4 of 4

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!